Combination of simvastatin and imatinib sensitizes the CD34+ cells in K562 to cell death

Chronic myeloid leukemia (CML) is a hematological malignancy, 95% of which is due to translocation between chromosomes 9 and 22 and the resulting bcr-abl fusion protein. Imatinib specifically binds to the bcr-abl and inhibits cancer cells. However, a subpopulation of the CML cells named leukemia ste...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical oncology (Northwood, London, England) London, England), 2011-06, Vol.28 (2), p.528-531
Hauptverfasser:	Chen, Rui, Xiao, Wei, Li, Ding, Mu, Shijie
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens, CD34 - metabolism Antineoplastic Combined Chemotherapy Protocols - pharmacology Benzamides Cell death Cell Death - drug effects Cell Line, Tumor Cell Separation Drug Resistance, Neoplasm - drug effects Drug Synergism Flow Cytometry Hematology Humans Imatinib Mesylate Internal Medicine Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Medicine Medicine & Public Health Neoplastic Stem Cells - drug effects Neoplastic Stem Cells - metabolism Oncology Original Paper Pathology Piperazines - administration & dosage Pyrimidines - administration & dosage Reactive Oxygen Species Simvastatin - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!